Arbutus offers an asymmetric biotech setup: a debt-free balance sheet, validated LNP patent monetization, and a competitive hepatitis B cure candidate priced below its legal and clinical optionality.
Overview
Arbutus Biopharma is a clinical-stage biotech targeting a functional cure for chronic hepatitis B through imdusiran and AB-101, while monetizing foundational lipid nanoparticle IP used in genetic medicines. Its LNP platform, validated by Alnylam’s Onpattro and recent Moderna settlement proceeds, provides near-term non-dilutive cash flows. The investment case blends high-risk clinical development with substantial legal/IP optionality, a strengthened balance sheet, and a large HBV market opportunity where finite curative regimens could replace lifelong suppressive therapy.